论文部分内容阅读
目的 探讨中等剂量联合化疗方案治疗老年人急性髓细胞白血病 (AML)的疗效。方法 对 16例全身情况较好、无明显重要器官功能损害、骨髓增生活跃的老年AML患者 ,采用中等剂量联合化疗方案 (HA、DA和米托蒽醌 +阿糖胞苷 )。结果 完全缓解 (CR)率为 5 6 .3%,有效率 6 8.8%;可评价的 8例平均CR期 10 .2个月 ,最长 38个月 ;平均生存期 7.3个月 ,最长 38个月 ;治疗相关死亡率 18.8%,骨髓抑制发生率 37.5 %。结论 对一般情况较好、无明显重要器官功能损害的老年AML病人 ,采用中等剂量联合化疗比较积极和合理 ,可提高CR率 ,延长生存期
Objective To investigate the effect of moderate-dose combined chemotherapy in the treatment of acute myeloid leukemia (AML) in the elderly. Methods A total of 16 elderly patients with AML with good systemic condition, no significant organ dysfunction and active myeloid hyperplasia were treated with moderate dose combination chemotherapy (HA, DA and mitoxantrone + cytarabine). Results The complete remission (CR) rate was 56.3% and the effective rate was 6 8.8%. The average CR rate of 10 evaluable patients was 10.2 months, the longest was 38 months. The average survival time was 7.3 months and the longest was 38 Month; treatment-related mortality rate was 18.8% and bone marrow suppression rate was 37.5%. Conclusions For elderly AML patients who are generally good and have no significant organ dysfunction, the moderate-dose combined chemotherapy is more positive and reasonable, which can improve the CR rate and prolong the survival period